Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Oric Pharmaceuticals (ORIC – Research Report), Shockwave Medical (SWAV – Research Report) and Exelixis (EXEL – Research Report).
Oric Pharmaceuticals (ORIC)
In a report released today, Matthew Biegler from Oppenheimer upgraded Oric Pharmaceuticals to Buy, with a price target of $14.00. The company’s shares closed last Monday at $6.90.
According to TipRanks.com, Biegler has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Oric Pharmaceuticals with a $17.17 average price target, which is a 144.9% upside from current levels. In a report issued on October 24, J.P. Morgan also maintained a Buy rating on the stock with a $17.00 price target.
See the top stocks recommended by analysts >>
Shockwave Medical (SWAV)
Oppenheimer analyst Suraj Kalia maintained a Sell rating on Shockwave Medical today and set a price target of $165.00. The company’s shares closed last Monday at $214.90.
According to TipRanks.com, Kalia is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Shockwave Medical with a $246.30 average price target.
Exelixis (EXEL)
In a report issued on November 3, Peter Lawson from Barclays maintained a Buy rating on Exelixis. The company’s shares closed last Monday at $20.84.
According to TipRanks.com, Lawson is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Exelixis with a $25.82 average price target, a 22.9% upside from current levels. In a report issued on October 23, Bank of America Securities also maintained a Buy rating on the stock with a $27.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ORIC:
- ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
- ORIC Earnings this Week: How Will it Perform?
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Oric announces poster presentation on initial Phase 1b ORIC-533 data
- Oric Pharmaceuticals price target raised to $16 from $13 at H.C. Wainwright
